Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione

DRUG2 trials

Sponsors

Eisai Limited, Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Conditions

Hepatocellular carcinomaadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionscolorectal cancerendometrial canceror other solid tumorwho failed prior line of palliative chemotherpay

Phase 1

An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

Active, not recruitingCTIS2023-510275-64-00

Eisai Limitedcolorectal cancer, endometrial cancer, Hepatocellular carcinoma +1

Start: 2023-05-31Target: 83Updated: 2025-11-07

Phase 3

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY

Active, not recruitingCTIS2024-512934-14-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

Start: 2016-11-07Target: 319Updated: 2025-06-23